China has a historical and deep expertise in processing ginseng, handling 97 percent of the world supply, and it is for this reason that the extraction process occurs outside of Canada. After this step the material is returned to Canada for the remainder of the manufacturing process, including Quality Assurance testing against Health Canada-established criteria, and every stage of the process meets or exceeds all applicable Canadian manufacturing regulatory requirements. A total of 42 quality tests are conducted on each batch of COLD-FX.
Clinical trials establishing COLD-FX’s safety, efficacy, and mechanism of action have been conducted at seven Canadian universities, and published in peer reviewed publications including the country’s foremost scientific journal, the Canadian Medical Association Journal.
Afexa Life Sciences is proud of COLD-FX's Canadian heritage and its role in helping to reduce the frequency, severity and duration of colds and flu by boosting the immune system.